Originally published as JCO Early Release 10.1200/JCO.2005.01.5180 on December 5 2005

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bachmann, I. M. Articles by Akslen, L. A. Search for Related Content PubMed PubMed Citation Articles by Bachmann, I. M. Articles by Akslen, L. A.

EZH2 Expression Is Associated With High Proliferation Rate and Aggressive Tumor Subgroups in Cutaneous Melanoma and Cancers of the Endometrium, Prostate, and Breast

From the the Gade Institute, Section of Pathology; Department of Surgical Sciences, University of Bergen; Department of Clinical Medicine, Section of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway; Department of Biochemistry, Swammerdam Institute for Life Sciences, University of Amsterdam, Amsterdam, the Netherlands

Address reprint requests Lars A. Akslen, MD, PhD, Children’s Hospital, Harvard Medical School, Vascular Biology Program, Karp Family Research Labs 12.125, 300 Longwood Ave, Boston, MA 02115-5737; e-mail: lars.akslen{at}childrens.harvard.edu or lars.akslen{at}gades.uib.no

PURPOSE: EZH2 is a member of the polycomb group of genes and important in cell cycle regulation. Increased expression of EZH2 has been associated previously with invasive growth and aggressive clinical behavior in prostate and breast cancer, but the relationship with tumor cell proliferation has not been examined in human tumors. The purpose of this study was to validate previous findings in a population-based setting, also including tumors that have not been studied previously.

PATIENTS AND METHODS: In our study of nearly 700 patients, we examined EZH2 expression and its association with tumor cell proliferation and other tumor markers, clinical features, and prognosis in cutaneous melanoma and cancers of the endometrium, prostate, and breast.

RESULTS: Strong EZH2 expression was associated with increased tumor cell proliferation in all four cancer types. Associations were also found between EZH2 and important clinicopathologic variables. EZH2 expression showed significant prognostic impact in melanoma, prostate, and endometrial carcinoma in univariate survival analyses, and revealed independent prognostic importance in carcinoma of the endometrium and prostate.

CONCLUSION: Our findings point at EZH2 as a novel and independent prognostic marker in endometrial cancer, and validate previous findings on prostate and breast cancer. Further, EZH2 expression was associated with features of aggressive cutaneous melanoma. The fact that EZH2 might identify increased tumor cell proliferation and aggressive subgroups in several cancers may be of practical interest because the polycomb group proteins have been suggested as candidates for targeted therapy. EZH2 expression should, therefore, be further examined as a possible predictive factor.

Supported by Norwegian Cancer Society, Norwegian Research Council, Meltzer Research Fund, and Helse Vest Research Fund.

Terms in blue are defined in the glossary, found at the end of this article and online at www.jco.org.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

This article has been cited by other articles:

				S. Fujii, K. Ito, Y. Ito, and A. Ochiai Enhancer of Zeste Homologue 2 (EZH2) Down-regulates RUNX3 by Increasing Histone H3 Methylation J. Biol. Chem., June 20, 2008; 283(25): 17324 - 17332. [Abstract] [Full Text] [PDF]

				H Vekony, F M Raaphorst, A P Otte, M van Lohuizen, C R Leemans, I van der Waal, and E Bloemena High expression of Polycomb group protein EZH2 predicts poor survival in salivary gland adenoid cystic carcinoma J. Clin. Pathol., June 1, 2008; 61(6): 744 - 749. [Abstract] [Full Text] [PDF]

				N. Nishikawa, M. Toyota, H. Suzuki, T. Honma, T. Fujikane, T. Ohmura, T. Nishidate, M. Ohe-Toyota, R. Maruyama, T. Sonoda, et al. Gene Amplification and Overexpression of PRDM14 in Breast Cancers Cancer Res., October 15, 2007; 67(20): 9649 - 9657. [Abstract] [Full Text] [PDF]

				V. K. Rajasekhar and M. Begemann Concise Review: Roles of Polycomb Group Proteins in Development and Disease: A Stem Cell Perspective Stem Cells, October 1, 2007; 25(10): 2498 - 2510. [Abstract] [Full Text] [PDF]

				A. Miremadi, M. Z. Oestergaard, P. D.P. Pharoah, and C. Caldas Cancer genetics of epigenetic genes Hum. Mol. Genet., April 15, 2007; 16(R1): R28 - R49. [Abstract] [Full Text] [PDF]

				S. J. Clark Action at a distance: epigenetic silencing of large chromosomal regions in carcinogenesis Hum. Mol. Genet., April 15, 2007; 16(R1): R88 - R95. [Abstract] [Full Text] [PDF]

				A. H. Ting, K. M. McGarvey, and S. B. Baylin The cancer epigenome--components and functional correlates Genes & Dev., December 1, 2006; 20(23): 3215 - 3231. [Abstract] [Full Text] [PDF]

				W. Fiskus, M. Pranpat, M. Balasis, B. Herger, R. Rao, A. Chinnaiyan, P. Atadja, and K. Bhalla Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells Mol. Cancer Ther., December 1, 2006; 5(12): 3096 - 3104. [Abstract] [Full Text] [PDF]

				L. Ding and C. G. Kleer Enhancer of Zeste 2 as a Marker of Preneoplastic Progression in the Breast Cancer Res., October 1, 2006; 66(19): 9352 - 9355. [Abstract] [Full Text] [PDF]